Acadia Pharmaceuticals | ACAD - 流动负债



金融业
股票价格
USD
资产
USD 1.56B
现金及等价物
USD 819.69M
销售成本
USD 26.23M
流动资产
USD 1.06B
流动负债
USD 277.11M
债务
USD 54.81M
EBIT
USD 17.39M
EBITDA
USD 35.76M
员工
653
EPS每股收益
USD 1.6
股本和储备
USD 917.27M
销售毛利
USD 257.76M
债务利息支出
USD 0
利息收入
USD 8.25M
贷款资金
USD 0
市值
USD 3.56B
净收入
USD 273.57M
营业费用
USD 266.6M
营业利润
USD 17.39M
普通股股本
USD 169.18M
PE价格收益
11.61
税前利润
USD 26.32M
销售收入
USD 284M
销售和管理费用
USD 146.73M
股票
USD 34.67M
贸易债权人
USD 10.9M
应收帐款人
USD 148.23M


流动负债 更改 日
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
ALKERMES USD 543.44M 69.08M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
Biogen USD 3.35B 59.4M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Cara Therapeutics USD 10.68M 9.48M 2025-06
Corcept Therapeutics USD 166.08M 6.18M 2025-12
Cytokinetics USD 202.45M 60.31M 2025-12
Eisai JPY 387.67B 9.42B 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Incyte USD 1.52B 176.44M 2025-12
J&J USD 54.13B 3.26B 2025-12
Moderna USD 1.99B 306M 2025-12
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Pfizer USD 36.6B 1.13B 2025-09
Prothena USD 51.44M 16.37M 2025-09
PTC Therapeutics USD 968.43M 102.18M 2025-12
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12